Transition from the reference adalimumab (Humira) to the FDA and EU-approved biosimilar adalimumab ABP 501 (Amgevita) was not associated with increased immunogenicity over a 72-week observation period in patients with rheumatoid arthritis, based on the results of a study presented at the European Congress of Rheumatology.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
